About: http://data.cimple.eu/news-article/0acfeb30995a41f9e2c4f950a1619756b38c2259f282914b8b60c3ad     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Europe's medicines regulator on Friday provisionally approved use of US biotech firm Regeneron's Covid-19 therapy, saying it prevented patients with from getting worse. Regeneron's synthetic antibody treatment was used to treat former US President Donald Trump after he contracted coronavirus last year. The European Medicines Agency said preliminary results showed treatment with REGN-COV2 reduced the amount of the virus in the back of the nose and throat and led to fewer medical visits. "The Agency concluded that... REGN-COV2 can be used for the treatment of confirmed Covid-19 in patients who do not require supplemental oxygen and who are at high risk of progressing to severe Covid-19," it said in a statement. REGN-COV2 is a combination of casirivimab and imdevimab, two monoclonal antibodies which is given to a patient via a drip, the EMA said. Monoclonal antibodies are lab-made versions of the body's natural infection-fighting defenses. The two antibodies have been designed to attach to the spike protein of the coronavirus at two different sites, stopping it from entering the body's cells, the EMA said. A rolling review of the two antibodies, which started on February 1 "was ongoing", the medicines regulator said, adding "once finalised it will be the basis for an EU marketing authorisation for this combination". The US-based Food and Drug Administration in November approved emergency use of REGN-COV2, experimentally used to treat Trump. On Thursday, France too announced it had distributed thousands of monoclonal antibody treatments to hospitals, with Health Minister Olivier Veran saying "there are new hopes... which strengthen our anti-Covid arsenal". The EMA however did not make an announcement Friday on the approval of Johnson & Johnson's coronavirus jab, which earlier this month applied for authorisation within the European Union. So far, three vaccines made by Pfizer/BioNTech, Moderna and AstraZeneca have been approved by the EMA. A US panel of independent experts were meeting Friday to discuss whether to grant J&J's covid shot the go-ahead in the United States. Friday's announcements followed the Amsterdam-based EMA's monthly meeting, where it also recommended the approval of six other medicines including the first oral treatment for patients with certain types of spinal muscular atrophy. This rare and often fatal genetic disease causes muscle weakness and progressive loss of movement. jhe/har
schema:headline
  • EU medicines regulator approves Regeneron virus therapy
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software